Intel stock extends gains after report of possible U.S. government stake
SAN JOSE - VSee Health, Inc. (NASDAQ:VSEE) has requested a hearing before a Nasdaq Listing Qualifications Panel to appeal a staff determination to delist the company’s common stock from the Nasdaq Capital Market, according to a press release issued Tuesday. The company’s stock, which InvestingPro data shows has fallen nearly 36% in the past week and is currently trading at $0.83, appears undervalued according to InvestingPro’s Fair Value analysis.
The telehealth solutions provider received a letter from Nasdaq on August 5, 2025, indicating non-compliance with filing requirements. The company has not filed its Annual Report on Form 10-K for the period ending December 31, 2024, and its Quarterly Report on Form 10-Q for the period ending March 31, 2025. InvestingPro analysis reveals concerning financial health indicators, with the company’s overall financial health score rated as WEAK and current ratio at 0.37, indicating potential liquidity challenges.
By requesting the hearing, VSee Health has automatically stayed the delisting for 15 days. The company plans to request a further stay pending the hearing, which if approved, would allow its stock to continue trading on the Nasdaq Capital Market.
The company acknowledged there is no assurance the Panel will grant its request for continued listing or an extended stay. If the appeal is unsuccessful, VSee Health’s common stock could become eligible to trade on the OTC Bulletin Board.
VSee Health describes itself as a provider of telehealth solutions specializing in virtual care, clinical review, and billing services. The company states it has deployed services in over 50 countries and serves clients including NASA, the US Department of Health and Human Services, and various healthcare organizations. Despite reporting revenue growth of 37.45% in the last twelve months, InvestingPro data shows the company faces profitability challenges with negative EBITDA of $0.94 million. Subscribers to InvestingPro can access 7 additional key insights about VSee Health’s financial position and market performance.
The information in this article is based on a press release statement from VSee Health.
In other recent news, VSee Health Inc. has faced significant challenges related to compliance with Nasdaq’s filing requirements. The company received a delisting notice from Nasdaq due to its failure to file both its annual report for the fiscal year ended December 31, 2024, and its quarterly report for the period ended March 31, 2025. VSee Health has been given a 60-day period to present a compliance plan, which could extend its deadline to October 13, 2025, if accepted. Despite these challenges, VSee Health’s stock saw a notable increase following the launch of its new AI doctor notes solution, which significantly reduces physician charting time. Additionally, the company has been selected to support a National Institutes of Health-funded clinical trial focusing on stroke recovery telerehabilitation. This trial involves 29 hospitals and aims to improve arm functionality in stroke survivors. These developments highlight the company’s ongoing efforts in innovation and research, even as it navigates compliance issues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.